Login to Your Account



Trial Design Trips Up Tivozanib, AVEO Pharma Stock Swoons

By Catherine Shaffer
Staff Writer

Thursday, February 14, 2013
Stock in AVEO Pharmaceuticals Inc. softened following a clinical trial update released in conjunction with the company's full year 2012 earnings. Trial design may have confounded results for tivozanib, which show overall survival (OS) trends favoring the comparator drug Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG), with OS of 28.8 months for tivozanib and 29.3 months for sorafenib (p = 0. 105).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription